
Brepocitinib met the primary endpoint in both trials, and Priovant plans to seek expanded approval in the first half of 2027.
Roivant and Priovant said brepocitinib met the primary endpoint in both Phase 3 CLARITY trials for non-infectious uveitis. The drug also showed statistically significant benefits on all key secondary endpoints.
Median time to treatment failure was more than 48 weeks for patients taking brepocitinib, compared with about 12 weeks for those on placebo. The results were reported for both trials, which together enrolled 371 patients.
Across the studies, 62% of brepocitinib patients achieved steroid-free quiescence at Week 48, compared with 20% on placebo. Among eyes with macular edema at the start, resolution by Week 48 occurred in 42% of eyes on brepocitinib and 4.8% on placebo.
The companies said the safety profile was consistent with previous brepocitinib trials, with no new safety signals. Priovant intends to file a supplemental New Drug Application for the treatment in the first half of 2027.
Roivant shares traded at $36.48, up 4.47% since the previous close, as of 16:28 UTC on Oct. 21.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.